Anemia is a common complication in CKD. It leads to a reduced quality of life, worse renal survival, increased morbidity and mortality, and higher costs. The prevalence of CKD anemia increases with   the progression of CKD to advanced stages, ranging from 40% in stage 3 to 70% in stage 5. High-dose ESAs pose safety concerns, including increased         cardiovascular risk indicating that alternative therapies may be needed. The drugs we are testing in this research are Punarnava Mandura Vati and Varuna-Shigru Kwatha which are selected as trial drug. This has been selected for this study because it acts as an anemia-correcting agent owing to its several components. Studies has also revealed that this drug is well tolerated among the patients without any side effects and untoward effects compared to allopathic drug in one of the clinical trials. Triphala, Trikatu, Chitraka, Vidanga, and Pippalimula have appetizing, digestive, and carminative properties which improve digestive power and ultimately absorption of the drug. Amalaki, Danti, Pippali, Punarnava, Kushta, and Daruharidra are documented as drugs having immunomodulatory action and antioxidant properties having the potential of providing beneficial health effects in anemia. In the traditional medical system, Punarnava is widely recognized for both its diuretic and reno-protective properties. Triphala has anti-inflammatory and anti-oxidant activity. By significantly restoring serum levels of urea, uric acid, creatinine, and creatinine clearance, Terminalia chebula safeguards renal function. Through its antioxidant capacity, it also protects against oxidative damage and prevents nephrotoxicity. Varuna having properties like Kashaya, Madhura, Tikta & Katu Rasa & Ruksha & laghu Guna and it is Ushna, Sleshmahara, Mutrakruchhahara, Ashmarighna, Vatahara, Agnideepana. Shigru having properties like Katu, Madhura, Tikta Rasa, Katu Vipaka, Ushna Virya, Tikshna, Laghu and Ushna Guna. It is Kapha-vatanasaka, Sothhara & Medohara. The following investigations will be carried out before & after treatment to rule out other pathogenesis and assessment the status of subjects. Routine blood and urine investigation, Lipid Profile and Liver function test (LFT) & Renal function test (RFT) and iron markers. The participation in this research is entirely voluntary. In this present research work, 30 clinically diagnosed and confirmed cases of Anemia Associated with Non-Dialysis Dependent Chronic Kidney Disease will be taken. Here in Group A, the patients will be advised to take (Standard of Care) for the duration of 90 days. In Group B, the patients will be advised to take Punarnava Mandura in the dosage of 2 vati twice a day after meal with butter milk. Each Vati weigh 500mg. Varuna-Shigru Kwatha will be given in the dosage of 40ml twice a day empty stomach in the early morning and after 5 hours of lunch for the duration of 90 days in addition to the (Standard of Care). PathyaApathya will be advised to the patients. The duration of the treatment is 12 weeks along with 2 weeks follow up.